| NCT00430898 | Cerimon Pharmaceuticals | Ulcerative Colitis | 2007-01 | PHASE2 |
| NCT05013034 | Fort Worth Clinical Sciences Working Group|TCU and UNTHSC School of Medicine | SARS-CoV-2 Acute Respiratory Disease|SARS-CoV2 Infection|Cytokine Storm | 2021-10-15 | PHASE2 |
| NCT03171831 | First Affiliated Hospital of Guangxi Medical University | Thalassemia Major | 2017-04-01 | PHASE4 |
| NCT00023244 | National Institute of Allergy and Infectious Diseases (NIAID)|Cooperative Clinical Trials in Pediatric Transplantation | End-Stage Renal Disease | 2001-01 | PHASE2 |
| NCT01049633 | National Institute of Allergy and Infectious Diseases (NIAID)|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Type 1 Diabetes Mellitus | | |
| NCT00284947 | Novartis | Kidney Transplantation|Adverse Effects | 2006-01 | PHASE4 |
| NCT00409656 | University Hospital Freiburg | Corneal Transplantation | 2003-12 | PHASE2 |
| NCT06480630 | Anhui Provincial Hospital | Acute Graft Versus Host Disease|Malignant Hematologic Neoplasm | 2024-07-01 | PHASE2 |
| NCT00975975 | Indiana University | Acute Myelogenous Leukemia|Acute Lymphocytic Leukemia|Chronic Myelogenous Leukemia|Chronic Lymphocytic Leukemia|Myelodysplasia|Non-Hodgkin´s Lymphoma|Hodgkin´s Disease|Multiple Myeloma|Myelofibrosis|Anemia, Aplastic|Hemoglobinuria, Paroxysmal | 2009-09 | PHASE2 |
| NCT00238901 | Novartis | Liver Transplant | 2002-12 | PHASE3 |
| NCT02366728 | Mustafa Khasraw, MBChB, MD, FRCP, FRACP | Glioblastoma|Astrocytoma, Grade IV|Giant Cell Glioblastoma|Glioblastoma Multiforme | 2015-10-12 | PHASE2 |
| NCT00434811 | National Institute of Allergy and Infectious Diseases (NIAID)|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Type 1 Diabetes Mellitus | 2006-10 | PHASE3 |
| NCT02464878 | Massachusetts General Hospital|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|University of Iowa | Kidney Transplant|Type 1 Diabetes | 2017-01 | PHASE2 |
| NCT04337593 | Beijing Tongren Hospital | Extranodal NK+T-cell Lymphoma | 2020-06-01 | PHASE2 |
| NCT00555321 | Bristol-Myers Squibb | Immunosuppression in Solid Organ Transplant | 2008-01 | PHASE2 |
| NCT00928811 | Drexel University College of Medicine|Novartis | End Stage Renal Disease | 2009-05 | PHASE2|PHASE3 |
| NCT00594308 | Indiana University | Acute Myelogenous Leukemia|Acute Lymphocytic Leukemia|Chronic Myelogenous Leukemia|Chronic Lymphocytic Leukemia|Myelodysplasia|Lymphoma, Non-Hodgkin´s|Mantle-Cell Lymphoma|Hodgkin´s Disease|Multiple Myeloma|Myelofibrosis | 2007-10 | NA |
| NCT00752479 | Mario Negri Institute for Pharmacological Research | Kidney Transplant | 2008-05 | PHASE1|PHASE2 |
| NCT02921789 | Astellas Pharma Global Development, Inc.|Kyowa Kirin Co., Ltd. | Kidney Transplantation|Primary Focal Segmental Glomerulosclerosis (FSGS) | 2017-05-22 | PHASE2 |
| NCT02723786 | GlaxoSmithKline | Kidney Transplantation (Status Post) | 2016-08-27 | PHASE2 |
| NCT00789308 | National Institute of Allergy and Infectious Diseases (NIAID)|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)|Clinical Islet Transplantation Consortium | Diabetes Mellitus, Type I | 2008-07-11 | PHASE2 |
| NCT05385432 | University Hospital, Tours | Renal Transplant Rejection|Induction Therapy | 2023-09-12 | PHASE3 |
| NCT01485055 | Nationwide Children´s Hospital | Graft Versus Host Disease|Steroid Refractory GVHD|Acute GVH Disease | 2011-12 | PHASE2 |
| NCT00790439 | National Institute of Allergy and Infectious Diseases (NIAID)|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Diabetes Mellitus, Type I | 2008-07 | PHASE2 |
| NCT01239563 | University of Oxford|Oxford University Hospitals NHS Trust|Genzyme, a Sanofi Company | Kidney Transplantation|Ischemia-Reperfusion Injury | 2011-01 | PHASE3 |
| NCT01856257 | National Institute of Allergy and Infectious Diseases (NIAID)|Clinical Trials in Organ Transplantation | Primary Renal Allograft Candidate|Kidney Transplantation | 2013-07 | PHASE2 |
| NCT00729768 | Genentech, Inc. | Kidney Transplantation | | PHASE2|PHASE3 |
| NCT02730715 | University of Pennsylvania | KIDNEY TRANSPLANTATION | 2010-11 | |
| NCT00658320 | Novartis | Kidney Transplantation | 2008-02 | PHASE3 |
| NCT00434850 | National Institute of Allergy and Infectious Diseases (NIAID)|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Diabetes Mellitus, Type 1 | 2006-10 | PHASE2 |
| NCT00369161 | Novartis | Renal Transplantation | 2006-06 | PHASE4 |
| NCT02492490 | Fuzhou General Hospital | Uremia | 2014-12 | PHASE1|PHASE2 |
| NCT00188825 | University Health Network, Toronto|Novartis | COPD|Emphysema|Alpha-1 Antitrypsan Deficiency | 2004-05 | PHASE3 |
| NCT01884571 | Emory University|ALS Association | Amyotrophic Lateral Sclerosis (ALS) | 2013-10 | PHASE2 |
| NCT00149890 | Novartis | Liver Transplantation|Infection | 2004-03 | PHASE3 |
| NCT01061996 | Cerimon Pharmaceuticals | Ulcerative Colitis | 2007-07 | PHASE2 |
| NCT00646425 | Cerimon Pharmaceuticals|PPD Development, LP | Non-infectious Uveitis | 2008-05 | PHASE2 |
| NCT00543569 | Astellas Pharma Inc | Kidney Transplantation | 2008-02 | PHASE2 |
| NCT00228020 | Novartis | Pediatric Kidney Transplantation | 2001-05 | PHASE3 |
| NCT03192657 | RenJi Hospital | Lung; Disease, Interstitial, With Fibrosis|Dermatomyositis | 2017-07 | PHASE2 |
| NCT02123108 | University of California, Los Angeles|Novartis | Liver Transplantation | 2011-01 | PHASE4 |
| NCT00956293 | Novartis Pharmaceuticals | Renal Transplantation | 2009-07 | PHASE4 |
| NCT01436305 | National Institute of Allergy and Infectious Diseases (NIAID)|Clinical Trials in Organ Transplantation | Kidney Transplantation|Renal Transplantation | 2011-09 | PHASE2 |
| NCT00890253 | Armin Goralczyk | Liver Transplantation|Chronic Renal Insufficiency | 2010-01 | PHASE2 |
| NCT00464555 | National Institute of Allergy and Infectious Diseases (NIAID)|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Type 1 Diabetes Mellitus | 2006-12 | PHASE2 |
| NCT01817322 | Samsung Medical Center | Chronic Renal Disease | 2011-06 | PHASE4 |
| NCT04404127 | King Faisal Specialist Hospital & Research Center | Kidney Transplantation | 2020-09-01 | PHASE4 |
| NCT00343226 | Novartis | Liver Transplantation | 2002-05 | PHASE4 |
| NCT00468117 | National Institute of Allergy and Infectious Diseases (NIAID)|National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) | Type 1 Diabetes Mellitus | 2007-01 | PHASE3 |
| NCT02342782 | City of Hope Medical Center|National Cancer Institute (NCI) | Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma|Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma|Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma|Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma|Refractory Cutaneous T-Cell Non-Hodgkin Lymphoma | 2020-06-08 | PHASE1 |
| NCT02056938 | Nantes University Hospital | Kidney Transplantation | 2014-06 | PHASE4 |
| NCT04104438 | Fady M Kaldas, M.D., F.A.C.S. | Asses Immunosuppression Modulation on Renal Recovery Post LT | 2021-01-15 | PHASE4 |
| NCT05139004 | City of Hope Medical Center|National Cancer Institute (NCI) | Acute Lymphoblastic Leukemia|Acute Myeloid Leukemia|Myelodysplastic Syndrome|Secondary Acute Myeloid Leukemia | 2022-07-19 | PHASE1 |
| NCT01476839 | City of Hope Medical Center|National Cancer Institute (NCI) | Recurrent Adult Hodgkin Lymphoma | 2012-11-09 | PHASE1 |
| NCT01780844 | Astellas Pharma Global Development, Inc.|Kyowa Kirin Co., Ltd. | Kidney Transplantation | 2013-03-05 | PHASE2 |
| NCT01842139 | University of Chicago|National Cancer Institute (NCI) | Adult Acute Myeloid Leukemia in Remission|Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities|Adult Acute Myeloid Leukemia With Del(5q)|Adult Acute Myeloid Leukemia With Inv(16)(p13;q22)|Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)|Adult Acute Myeloid Leukemia With t(16;16)(p13;q22)|Adult Acute Myeloid Leukemia With t(8;21)(q22;q22) | 2011-12-05 | PHASE1 |
| NCT00251004 | Novartis | Kidney Transplantation|Graft Rejection | 2005-10 | PHASE3 |
| NCT01625377 | Novartis Pharmaceuticals | Liver Transplantation | 2012-12 | PHASE3 |
| NCT06066840 | The First Affiliated Hospital of Soochow University|The First Affiliated Hospital with Nanjing Medical University|The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School|Affiliated Hospital of Nantong University | Safety and Efficacy | 2022-08-01 | PHASE4 |
| NCT00378014 | Novartis Pharmaceuticals | Liver Transplantation | 2006-08 | PHASE3 |
| NCT02894606 | University Hospital, Brest | Renal Transplant | 2015-02 | |
| NCT00154284 | Novartis | Organ Transplantation, Renal Transplantation | 2005-07 | PHASE3 |
| NCT00302497 | McGill University Health Centre+Research Institute of the McGill University Health Centre | Kidney Transplant | 2007-04 | PHASE3 |
| NCT00468403 | National Institute of Allergy and Infectious Diseases (NIAID)|Clinical Islet Transplantation Consortium | Type 1 Diabetes Mellitus | 2008-10 | PHASE2 |
| NCT00634920 | Novartis Pharmaceuticals | Renal Function | 2008-03 | PHASE4 |
| NCT00724022 | University Hospital Freiburg|Roche Pharma AG|Astellas Pharma GmbH|Genzyme, a Sanofi Company | Disorder Related to Renal Transplantation | 2008-06 | PHASE4 |
| NCT03006419 | Coordinación de Investigación en Salud, Mexico | Kidney Transplant Rejection|Kidney Transplant; Complications | 2016-12-01 | PHASE4 |
| NCT00965094 | Novartis Pharmaceuticals | Chronic Renal Failure | 2009-12 | PHASE4 |
| NCT03794492 | Chong Kun Dang Pharmaceutical | Kidney Transplant | 2018-03-31 | PHASE4 |
| NCT04773392 | University of Southern California|Veloxis Pharmaceuticals | Kidney Transplantation|Kidney Transplant Rejection | 2021-11-23 | PHASE4 |
| NCT01011205 | Astellas Pharma Inc | Liver Transplantation | 2009-09-30 | PHASE3 |
| NCT02492308 | Fuzhou General Hospital | Living-relative Kidney Transplantation | 2014-12 | PHASE1|PHASE2 |
| NCT00626483 | Gary Archer Ph.D.|National Cancer Institute (NCI) | Malignant Neoplasms Brain | 2007-04-24 | PHASE1 |
| NCT00113269 | Astellas Pharma Inc | Kidney Transplantation | 2005-05 | PHASE4 |
| NCT00149994 | Novartis Pharmaceuticals | Liver Transplant | 2002-12 | PHASE4 |
| NCT00296244 | Thomas Jefferson University|Novartis Pharmaceuticals | Liver Cirrhosis|Liver Transplant Disorder | 2006-02 | PHASE4 |
| NCT02459977 | Asan Medical Center | Kidney Transplantation | 2012-04 | NA |
| NCT00563108 | Hospital Authority, Hong Kong|Novartis Pharmaceuticals|The Hong Kong Blood Cancer Foundation | Graft vs Host Disease|Hematopoietic Stem Cell Transplantation | 2004-06 | NA |
| NCT01526096 | University of Chicago | Myeloma | 2011-07-12 | PHASE1 |
| NCT03663335 | Novartis Pharmaceuticals | Kidney Transplantation | 2018-11-28 | PHASE2 |
| NCT06374095 | Mario Negri Institute for Pharmacological Research | Kidney Replacement | 2024-07-30 | |
| NCT06087003 | Gang Chen|Zhejiang University|First Affiliated Hospital, Sun Yat-Sen University|The First Affiliated Hospital of Zhengzhou University|Changhai Hospital | Kidney Transplant Rejection|Pediatric Kidney Disease | 2013-03-03 | |